[1]廖翎帆,龚华,易明,等.不同起始量肺表面活性物质治疗新生儿呼吸窘迫综合征的多中心临床疗效比较[J].第三军医大学学报,2016,38(04):411-415.
 Liao Lingfan,Gong Hua,Yi Ming,et al.Difference of multi-center controlled clinical efficacy in treatment of neonatal respiratory distress syndrome with different initial doses of pulmonary surfactant[J].J Third Mil Med Univ,2016,38(04):411-415.
点击复制

不同起始量肺表面活性物质治疗新生儿呼吸窘迫综合征的多中心临床疗效比较(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第04期
页码:
411-415
栏目:
临床医学
出版日期:
2016-02-29

文章信息/Info

Title:
Difference of multi-center controlled clinical efficacy in treatment of neonatal respiratory distress syndrome with different initial doses of pulmonary surfactant
作者:
廖翎帆龚华易明龙华陈文周利刚钟晓云罗茜
重庆市妇幼保健院新生儿科; 重庆三峡中心医院妇儿分院新生儿科;重庆市涪陵中心医院新生儿科
Author(s):
Liao Lingfan Gong Hua Yi Ming Long Hua Chen Wen Zhou Ligang Zhong Xiaoyun Luo Qian

Department of Neonatology, Chongqing Health Centre for Women and Children, Chongqing, 400013; Department of Neonatology, Chongqing Three Gorges Central Hospital, Chongqing, 404000; Department of Neonatology, Fuling Center Hospital of Chongqing City, Chongqing, 408000, China

关键词:
肺表面活性物质新生儿呼吸窘迫综合征早产儿多中心研究
Keywords:
pulmonary surfactant neonatal respiratory distress syndrome premature multi-center controlled clinical trials
分类号:
R722.563.8;R972.6
文献标志码:
A
摘要:

目的      探讨不同起始量的肺表面活性物质(pulmonary surfactant, PS)治疗新生儿呼吸窘迫综合征(neonatal respiratory distress syndrome,NRDS)的疗效及差异。      方法      采用前瞻性、多中心对照临床研究方法,按多阶段分层随机抽样的方法,收集三家医院新生儿病房收治的143例新生儿呼吸窘迫综合征的患儿,且使用肺表面活性物质(商品名:珂立苏)治疗,采用完全随机设计的方法分成对照组和实验组,分别使用起始剂量为70 mg/kg 和100 mg/kg 的PS进行治疗,检测并记录使用PS前后不同时间血气分析结果、胸片结果、重复使用PS的次数、并发症的发生、机械通气时间、用氧时间及住院天数等指标。      结果      ①两组用药后需氧浓度、PaO2、PaCO2、胸片结果均较用药前有好转(P<0.05);② PS100 组应用PS后12、24、36 h较PS70组对氧的需求更低(P<0.05),PO2及PCO2改善更明显(P<0.05);③ PS100 组应用PS后24 h,胸片情况较PS70组明显好转(P<0.05);④PS100组在机械通气时间、用氧时间方面均低于PS70组(P0.05)。      结论      应用肺表面活性物质治疗NRDS起始剂量为100 mg/kg 的疗效优于70 mg/kg。

Abstract:

Objective      To investigate the difference of clinical efficacy in treatment of neonatal respiratory distress syndrome (NRDS) with different initial doses of pulmonary surfactant (PS).       Methods      Prospective multi-center controlled clinical trials and multi-stage stratified random sampling were employed, and 143 cases of NRDS treated with PS from 3 NICUs were enrolled in the trails. The neonates were randomly divided into 2 groups, which were treated with initial dose of PS at 70 mg/kg (PS70) and at 100 mg/kg (PS100), respectively. Blood gas analysis, chest X-ray results, repeated use of PS, complication occurrence, duration of mechanical ventilation, oxygen therapy and hospitalization were analyzed.       Results      The data demonstrated that PaO2, PaCO2 and chest X-ray results were improved in both groups after PS treatment (P<0.05). PS100 group had lower oxygen demand (P<0.05) at 12, 24 h and 36 h after PS administration compared with PS70 group, and PO2 and PCO2 were improved more significantly in PS100 group (P<0.05). PS100 group showed significantly improved chest X-ray results at 24 h after PS administration compared with PS70 group (P<0.05). Duration of mechanical ventilation and oxygen therapy were reduced more in PS100 group than in PS70 group (P<0.05).       Conclusion      PS exerts better clinical efficacy in NRDS at the initial dose of 100 mg/kg than at 70 mg/kg.

参考文献/References:

[1]陈超. 新生儿呼吸窘迫综合征[M]//邵肖梅, 叶鸿瑁, 丘小汕. 实用新生儿学. 4版.北京:人民卫生出版社, 2011: 395-398.
[2]刘传合, 董声焕, 徐辉, 等. 两种肺表面活性剂药效的实验比较[J]. 中国新药杂志, 1997, 6(2): 145-148.
[3]Cogo P E, Facco M, Simonato M, et al. Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome[J]. Pediatrics, 2009, 124(5): e950-e957. DOI:10.1542/peds.2009-0126
[4]Tsakalidis C, Giougki E, Karagianni P, et al. Is there a necessity for multiple doses of surfactant for respiratory distress syndrome of premature infants?[J]. Turk J Pediatr, 2012, 54(4): 368-375.
[5]Kamath B D, Macguire E R, McClure E M, et al. Neonatal mortality from respiratory distress syndrome: lessons for low-resource countries[J]. Pediatrics, 2011, 127(6): 1139-1146. DOI:10.1542/peds.2010-3212
[6]Ghaemi S, Mohamadymasodi M, Kelishadi R. 表面活性物质替代治疗新生儿呼吸窘迫综合征的疗效评估[J].中国当代儿科杂志,2009, 11(3): 188-190.
[7]Ruegger C, Hegglin M, Adams M, et al. Population based trends in mortality, morbidity and treatment for very preterm- and very low birth weight infants over 12 years[J]. BMC Pediatr, 2012, 12: 17. DOI:10.1186/1471-2431-12-17
[8]董声焕, 孙眉月, 寇同欣, 等. 肺表面活性剂(珂立苏)治疗新生儿呼吸窘迫综合征多中心临床试验[J]. 中国小儿急救医学, 2009, 16(2): 120-124. DOI:10.3760/cma.j.issn.1673-4912.2009.02.008
[9]李杰, 樊寻梅, 宋国维, 等. 肺表面活性制剂治疗新生儿呼吸窘迫综合征多中心临床观察[J]. 中华儿科杂志, 2000, 38(6): 344-347.
[10]珂立苏治疗新生儿呼吸窘迫综合征多中心协作组. 肺表面活性物质治疗新生儿呼吸窘迫综合征时有效减少肺出血发生率的应用时限选择的多中心回顾性研究[J]. 第三军医大学学报, 2014, 36(11): 1203-1207.

相似文献/References:

[1]李禄全,余加林,陈静宇,等.牛肺表面活性物质治疗早产儿呼吸窘迫综合征对脑血流动力学的影响[J].第三军医大学学报,2010,32(21):2333.
 Li Luquan,Yu Jialin,Chen Jingyu,et al.Effect of bovine pulmonary surfactant on cerebral hemodynamics in premature neonates with respiratory distress syndrome[J].J Third Mil Med Univ,2010,32(04):2333.
[2]彭珠芸,俞丽丽,郑英如,等.妊娠肝内胆汁淤积综合征相关新生儿肺损伤的危险因素分析[J].第三军医大学学报,2012,34(02):134.
 Peng Zhuyun,Yu Lili,Zheng Yingru,et al.Risk factors of intrahepatic cholestasis of pregnancy-induced neonatal lung injury[J].J Third Mil Med Univ,2012,34(04):134.
[3]珂立苏治疗新生儿呼吸窘迫综合征多中心协作组.肺表面活性物质治疗新生儿呼吸窘迫综合征时有效减少肺出血发生率的应用时限选择的多中心回顾性研究[J].第三军医大学学报,2014,36(11):1203.
 Multi-center Cooperative Group for Calf Pulmonary Surfactant in Treatment of Neonatal Respiratory Distress Syndrome.Timing for initial therapy of pulmonary surfactant to reduce pulmonary hemorrhage in neonatal respiratory distress syndrome: a multi-center retrospective study[J].J Third Mil Med Univ,2014,36(04):1203.

更新日期/Last Update: 2016-01-29